Tafasitamab for kids with high-risk B-cell leukemia after relapse
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1/2 study tests tafasitamab in children and teens with B-lineage acute lymphoblastic leukemia (ALL) that has come back or did not respond. It is mainly for patients with specific high-risk leukemia changes and/or leukemia markers that stay after stem cell transplant or CAR T-cell therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 3 and 17 years old when starting the study
- Have B-lineage ALL confirmed by a leukemia test showing CD19-positive disease
- Have had treatment that includes a stem cell transplant and/or CAR T-cell therapy, with persistent or newly emerging leukemia markers after treatment, or did not reach enough molecular remission before transplant
- Not have a clear “frank relapse” with more than 5% leukemia blasts
- Not have Philadelphia chromosome-positive ALL
- Have adequate heart, kidney, and liver function on screening blood tests (and be free of certain serious infections)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
This Phase 1 study tests a CAR-T cell treatment made to target CD19 in children and young adults whose leukemia or lymphoma has come back or did not respond to prior treatment. It aims to see how the treatment works and how safe it is in this age group.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
This trial is testing a new CAR-T cell therapy (Senl_B19) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. It targets a protein called CD19 on leukemia cells to help your immune system attack the cancer.
Hear when a new ALL, Childhood B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.